Perrigo Company plc (NYSE:PRGO) Given Average Recommendation of “Hold” by Brokerages

Shares of Perrigo Company plc (NYSE:PRGO) have been given a consensus rating of “Hold” by the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $19.3333.

Several analysts recently commented on the company. Canaccord Genuity Group decreased their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings lowered Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Finally, Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Hedge Funds Weigh In On Perrigo

Several institutional investors have recently bought and sold shares of PRGO. Amundi raised its position in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after purchasing an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new position in Perrigo in the 1st quarter valued at $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after purchasing an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Price Performance

Shares of PRGO stock opened at $11.15 on Wednesday. The stock’s fifty day simple moving average is $11.15 and its 200 day simple moving average is $12.48. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -0.85, a P/E/G ratio of 1.37 and a beta of 0.51. Perrigo has a one year low of $9.23 and a one year high of $28.43.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.Perrigo’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts expect that Perrigo will post 2.12 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be given a $0.29 dividend. The ex-dividend date is Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 10.4%. Perrigo’s payout ratio is presently -8.85%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.